미럼 파마슈티컬스(MIRM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $100.64 (+1.89%), 시가총액 $5.83B, 52주 범위 $43.73 ~ $111.39.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of p
미럼 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
미럼 파마슈티컬스의 현재 주가는 $100.64 (+1.89%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
미럼 파마슈티컬스의 시가총액은 약 $5.83B입니다.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is L